Categories: All postsAnalysts

Hydreight Technologies: Buy, Sell or Hold?

Beacon Securities analyst Gabriel Leung says a U.S. regulatory review of compounded peptides could become an incremental growth driver for Hydreight Technologies (Hydreight Technologies Stock Quote, Chart, News, Analysts, Financials TSXV:NURS).

In a July 24 update, Leung maintained his “Speculative Buy” rating and $10.00 target on Hydreight. His target is based on 17 times calendar 2027 estimated EV/EBITDA.

Leung said the FDA’s Pharmacy Compounding Advisory Committee voted to recommend that four peptides be considered for inclusion on the 503A Bulks List. If the FDA adopts the recommendation, 503A compounding pharmacies could eventually compound those peptides with a valid prescription.

The committee is scheduled to review three additional peptides, including Semax, Epitalon and Emideltide, with five more peptides expected to be reviewed around the end of February 2027.

Leung said the committee’s recommendation is advisory and not binding, with the FDA still required to accept the recommendation, begin rulemaking or reject it.

“Given that current HHS leadership initiated this review process and has publicly advocated for broader peptide use, most industry and regulatory observers believe the FDA is more-than-likely to adopt the committee’s recommendations,” Leung said.

Leung said the developments could create a demand tailwind for Hydreight’s VSDHOne platform and add more treatment options to its offering.

The analyst said Hydreight’s calendar 2026 guidance of $150-million in baseline revenue does not depend on the peptide catalyst, making the potential benefit incremental to the company’s growth outlook, particularly in calendar 2027.

For Q2, Leung forecasts revenue of $27.4-million and Adjusted EBITDA of $3.4-million. Hydreight is expected to report Q2 results in late August.

Leung expects Hydreight to generate Adjusted EBITDA of $22.6-million on revenue of $149.5-million in fiscal 2026, improving to Adjusted EBITDA of $31.6-million on revenue of $198.2-million in fiscal 2027.

 

-30-

Tagged with: nurs
Rod Weatherbie

Rod Weatherbie is a journalist based in Prince Edward Island. Since 2004, he has written extensively about the Canadian property and casualty insurance landscape. He was also a founder and contributing editor for a Toronto-based arts website and a PEI-based food magazine. His fiction and poetry have been featured in The Fiddlehead, The Antigonish Review, and Juniper.

Recent Posts

Can you make money with Metatek-Group stock?

Metatek-Group’s (Metatek-Group Stock Quote, Chart, News, Analysts, Financials TSX:MTEK) strong sequential revenue growth and expectations for a further improvement in… [Read More]

3 hours ago

Ascend Wellness Holdings: Buy, Sell or Hold?

Ascend Wellness Holdings’ (Ascend Wellness Holdings Stock Quote, Chart, News, Analysts, Financials CSE:AAWH.U) return to year-over-year revenue growth and improving… [Read More]

3 hours ago

RBC raises price target on Tidewater Renewables to $31.00

RBC Capital Markets analyst Maurice Choy raised his target on Tidewater Renewables (Tidewater Renewables Stock Quote, Chart, News, Analysts, Financials… [Read More]

3 hours ago

Apotex Health: this analyst just raised his price target

RBC Capital Markets analyst Douglas Miehm raised his target for Apotex Health (Apotex Health Stock Quote, Chart, News, Analysts, Financials… [Read More]

4 hours ago

Magellan Aerospace: Buy, Sell or Hold?

Magellan Aerospace’s (Magellan Aerospace Corp. Stock Quote, Chart, News, Analysts, Financials TSX:MAL) stronger-than-expected third-quarter results and potential opportunities from increased… [Read More]

4 hours ago

Is Cargojet (TSX:CJT) a buy right now?

Cargojet's (Cargojet Stock Quote, Chart, News, Analysts, Financials TSX:CJT) stronger-than-expected third-quarter results and ability to maintain margins despite higher fuel… [Read More]

4 hours ago